Internal Medicine, Medical Oncology · Lady Lake, FL
NPI
1356332506
Since 2005
Specialty
Internal Medicine, Medical Oncology
Code 207RX0202X
Group practices
1
Medicare group memberships
Hospitals
3
Hospital affiliations
1400 N US Highway 441 Ste 540
Lady Lake, FL, 32159
Phone (352) 753-9777
Groups this clinician bills Medicare through
Medicare paid, 2024
$8.5M
538,934 services
Medicare patients, 2024
2,085
Average age 77
Drug cost, 2024
$11.5M
3,033 prescriptions
Company payments, 2025
$39K
From 52 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Maen A Hussein was code Q0138 (injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use)), 109,650 times for 118 patients. In total Maen A Hussein billed 538,934 services in 200 codes, and Medicare paid $8.5M.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2026-01-30.
| Code | Setting | Services | Patients | Paid per service | Medicare paid |
|---|
| Q0138 Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 109,650 | 118 | $0.27 | $30K |
| Q5110 Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram | Office | 42,000 | 33 | $0.22 | $9,136 |
| J9299 Injection, nivolumab, 1 mg | Office | 25,240 | 15 | $24.39 | $616K |
| J9271 Injection, pembrolizumab, 1 mg | Office | 21,200 | 24 | $44.53 | $944K |
| J0185 Injection, aprepitant, 1 mg | Office | 16,380 | 37 | $1.33 | $22K |
| J0897 Injection, denosumab, 1 mg | Office | 14,580 | 108 | $20.55 | $300K |
| J9267 Injection, paclitaxel, 1 mg | Office | 14,509 | 18 | $0.08 | $1,166 |
| Q5101 Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram | Office | 14,160 | 12 | $0.27 | $3,765 |
| J9144 Injection, daratumumab, 10 mg and hyaluronidase-fihj | Office | 14,040 | 13 | $39.44 | $554K |
| J1756 Injection, iron sucrose, 1 mg | Office | 13,400 | 29 | $0.18 | $2,393 |
| J9263 Injection, oxaliplatin, 0.5 mg | Office | 13,126 | 11 | $0.06 | $731 |
| J9173 Injection, durvalumab, 10 mg | Office | 8,652 | 12 | $63.57 | $550K |
| J1434 Injection, fosaprepitant (focinvez), 1 mg | Office | 8,100 | 23 | $2.30 | $19K |
| J1569 Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | Office | 8,082 | 31 | $35.85 | $290K |
| J0885 Injection, epoetin alfa, (for non-esrd use), 1000 units | Office | 7,270 | 41 | $6.42 | $47K |
By year: 2022 $8.6M for 603,042 services; 2023 $9.0M for 562,980 services; 2024 $8.5M for 538,934 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 4,851 | 1,483 | $7.60 | $37K |
| 36415 Venipuncture Blood Collection | 4,616 | 1,515 | $8.65 | $40K |
| 85610 Clinical Chemistry | 96 | 15 | $4.20 | $403 |
| 81003 Clinical Chemistry | 89 | 39 | $2.20 | $196 |
| 85045 Blood Count | 51 | 42 | $3.91 | $199 |
Medicare prescription drug claims, 2024
In 2024, the drug Maen A Hussein prescribed most often to Medicare patients was Anastrozole, with 462 prescriptions and refills. In total Maen A Hussein wrote 3,033 Medicare prescriptions that cost $11.5M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Anastrozole Generic | 462 | 1,283 | 137 | $9,138 |
| Ondansetron Odt Ondansetron | 155 | 167 | 90 | $4,164 |
| Revlimid Lenalidomide | 154 | 154 | 16 | $2.5M |
| Eliquis Apixaban | 133 | 239 | 39 | $134K |
| Gabapentin Generic | 117 | 146 | 25 | $1,333 |
| Imbruvica Ibrutinib | 92 | 92 | Under 11 | $992K |
| Oxycodone Hcl Generic | 84 | 84 | 30 | $1,084 |
| Prochlorperazine Maleate Generic | 77 | 79 | 58 | $1,338 |
| Letrozole Generic | 74 | 188 | 21 | $2,199 |
| Dexamethasone Generic | 70 | 84 | 49 | $1,376 |
| Hydroxyurea Generic | 68 | 191 | 21 | $2,015 |
| Acyclovir Generic | 60 | 110 | 17 | $1,457 |
| Ibrance Palbociclib | 59 | 59 | 12 | $945K |
| Prednisone Generic | 58 | 130 | 30 | $541 |
| Brukinsa Zanubrutinib | 57 | 57 | Under 11 | $830K |
Brand drugs: 968 claims; generic drugs: 2,065 claims; opioid claims: 216.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Maen A Hussein $39K ($35K in general payments such as food, travel and fees and $4,360 for research) from 52 companies. The largest payer was Janssen Biotech, Inc. with $20K.
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. JNJ | 6 | $20K |
| Pfizer Inc. PFE | 17 | $8,234 |
| E.R. Squibb & Sons, L.L.C. BMY | 11 | $4,164 |
| Stemline Therapeutics Inc. | 2 | $1,573 |
| BeOne Medicines USA, Inc. ONC | 7 | $1,284 |
| Genentech USA, Inc. ROG.SW | 3 | $1,113 |
| Abbvie Inc. ABBV | 3 | $338 |
| Adc Therapeutics America, Inc. | 2 | $266 |
| Celgene Corporation BMY | 7 | $199 |
| CVRx, Inc. CVRX | 1 | $178 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.